CAAR T-cell therapy offers a more targeted route for neurological autoimmune diseases
Researchers at DZNE and Charité—Universitätsmedizin Berlin are working on a targeted therapy for neurological autoimmune diseases. So far, they have successfully tested their approach in mouse studies involving two such conditions. Their concept is based on deliberately modified immune cells, so-called CAAR T cells, designed to eliminate only the immune cells responsible for causing disease.
Researchers from DZNE and Charité—Universitätsmedizin Berlin are developing a targeted therapy for neurological autoimmune diseases using CAAR T cells. This therapy specifically targets immune cells that cause disease, eliminating them while leaving other essential cells unaffected. The team has successfully tested this approach in mouse models of two neurological autoimmune disorders: myasthenia gravis and anti-NMDA receptor encephalitis.
In myasthenia gravis, the condition involves communication issues between nerves and muscles, while anti-NMDA receptor encephalitis disrupts signal transmission among brain neurons. Conventional treatments for these diseases typically involve removing harmful antibodies from the blood or broadly suppressing the immune system, but these methods often have limited long-term effectiveness and can cause side effects.
The DZNE and Charité researchers aim to refine their approach for clinical trials, focusing on manufacturing CAAR T cells under strict quality standards and ensuring their safety.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
